Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

NCT01836653 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

122

Enrollment

OTHER

Sponsor class

Conditions

Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer

Interventions

DRUG: Bevacizumab
DRUG: Cetuximab
DRUG: L-OHP
DRUG: l-LV
DRUG: 5-FU
DRUG: 5-FU

Sponsor

EPS Corporation